NCCN 指南解读：肾癌，第 1.2021 版。
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
机构信息
Memorial Sloan Kettering Cancer Center.
The University of Texas MD Anderson Cancer Center.
出版信息
J Natl Compr Canc Netw. 2020 Sep;18(9):1160-1170. doi: 10.6004/jnccn.2020.0043.
Abstract
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for genetic testing, surveillance, and/or treatment options for patients who are suspected or confirmed to have one of these syndromes.
摘要
美国国家综合癌症网络（NCCN）肾癌指南为肾细胞癌（RCC）患者的诊断评估、分期和治疗提供了多学科建议。本 NCCN 指南要点重点介绍了指南的最新更新，包括对复发或 IV 期 RCC 患者某些系统治疗建议的更改。它们还讨论了指南中新增一节的内容，该节确定并描述了最常见的遗传性 RCC 综合征，并为疑似或确诊患有这些综合征之一的患者提供了基因检测、监测和/或治疗选择的建议。
相似文献
1
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.NCCN 指南解读：肾癌，第 1.2021 版。
J Natl Compr Canc Netw. 2020 Sep;18(9):1160-1170. doi: 10.6004/jnccn.2020.0043.
2
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.NCCN 指南®洞察：肾癌，第 2.2024 版。
J Natl Compr Canc Netw. 2024 Feb;22(1):4-16. doi: 10.6004/jnccn.2024.0008.
3
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.《肾癌临床实践指南》第 3 版 2022 年版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Jan;20(1):71-90. doi: 10.6004/jnccn.2022.0001.
4
Diagnosis and Management of Hereditary Renal Cell Cancer.遗传性肾细胞癌的诊断与管理
Recent Results Cancer Res. 2016;205:85-104. doi: 10.1007/978-3-319-29998-3_6.
5
Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.遗传性平滑肌瘤病和肾细胞癌：185 名受累个体队列的临床、分子和筛查特征。
Eur Urol Oncol. 2020 Dec;3(6):764-772. doi: 10.1016/j.euo.2019.11.002. Epub 2019 Dec 9.
6
Genetic kidney cancer syndromes.遗传性肾癌综合征。
J Natl Compr Canc Netw. 2014 Sep;12(9):1347-55. doi: 10.6004/jnccn.2014.0129.
7
Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.遗传性肾细胞癌综合征：诊断、监测和管理。
World J Urol. 2018 Dec;36(12):1891-1898. doi: 10.1007/s00345-018-2288-5. Epub 2018 Apr 21.
8
Inherited forms of renal cell carcinoma.遗传性肾细胞癌
Scand J Surg. 2004;93(2):103-11. doi: 10.1177/145749690409300204.
9
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.NCCN 指南解读：肾癌，第 2.2020 版。
J Natl Compr Canc Netw. 2019 Nov 1;17(11):1278-1285. doi: 10.6004/jnccn.2019.0054.
10
Inherited kidney cancer syndromes.遗传性肾癌综合征
Curr Opin Urol. 2019 Jul;29(4):334-343. doi: 10.1097/MOU.0000000000000646.
引用本文的文献
1
Survival benefits of Cytoreductive Nephrectomy in patients with metastatic renal cell carcinoma: evidence from a SEER-based retrospective cohort study.减瘤性肾切除术对转移性肾细胞癌患者的生存益处：基于监测、流行病学和最终结果（SEER）数据库的回顾性队列研究证据
PLoS One. 2025 Jul 15;20(7):e0318896. doi: 10.1371/journal.pone.0318896. eCollection 2025.
2
Renal cell carcinoma accompanied by aldosterone-secreting contralateral adrenal metastasis: a case report.肾细胞癌伴分泌醛固酮的对侧肾上腺转移：一例报告
J Med Case Rep. 2025 Jul 9;19(1):331. doi: 10.1186/s13256-025-05396-8.
3
Long-term resident adipose-derived stromal stem cells in the microenvironment remodeling BLCA cell stemness and EMT promotes bladder cancer progression.长期驻留的脂肪来源基质干细胞在微环境重塑中使膀胱癌细胞干性和上皮-间质转化增强，从而促进膀胱癌进展。
Sci Rep. 2025 Jul 2;15(1):23049. doi: 10.1038/s41598-025-07387-7.
4
Identification of CXCR4 as a potential preventive gene in clear cell renal cell carcinoma from machine learning and immune analysis.通过机器学习和免疫分析确定CXCR4作为透明细胞肾细胞癌潜在预防基因
Sci Rep. 2025 Jul 1;15(1):21321. doi: 10.1038/s41598-025-08199-5.
5
Expression of PSTPIP1 in Renal Cell Carcinoma and Its Prognostic Value.PSTPIP1在肾细胞癌中的表达及其预后价值。
Biochem Genet. 2025 Jul 1. doi: 10.1007/s10528-025-11163-7.
6
Surgical Management of Renal Cell Carcinoma in Transplanted Kidneys-A Narrative Review.移植肾肾细胞癌的外科治疗——一项叙述性综述
Cancers (Basel). 2025 May 31;17(11):1864. doi: 10.3390/cancers17111864.
7
Impact of thermal ablation/cryoablation treatment on prognosis among patients with kidney cancer: a SEER database-based cohort study.热消融/冷冻消融治疗对肾癌患者预后的影响：一项基于监测、流行病学和最终结果（SEER）数据库的队列研究
Eur J Med Res. 2025 May 19;30(1):391. doi: 10.1186/s40001-025-02592-6.
8
A novel multigene panel (Sig27) robustly predicts poor prognosis of renal cell carcinoma via high-level associations with immunosuppressive features.一种新型多基因检测板（Sig27）通过与免疫抑制特征的高度关联有力地预测肾细胞癌的不良预后。
BJC Rep. 2025 Mar 17;3(1):16. doi: 10.1038/s44276-025-00128-3.
9
Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma.用于预测转移性透明细胞肾细胞癌免疫治疗疗效的双人类内源性逆转录病毒分层系统。
J Immunother Cancer. 2025 Jan 22;13(1):e010386. doi: 10.1136/jitc-2024-010386.
10
The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis.贝利尤单抗抑制剂治疗晚期或转移性透明细胞肾细胞癌患者的疗效和安全性：一项荟萃分析。
BMC Pharmacol Toxicol. 2024 Dec 20;25(1):100. doi: 10.1186/s40360-024-00828-5.
本文引用的文献
1
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
2
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
3
Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.帕唑帕尼治疗 von Hippel-Lindau 病患者的疗效：单臂、单中心、2 期临床试验。
Lancet Oncol. 2018 Oct;19(10):1351-1359. doi: 10.1016/S1470-2045(18)30487-X. Epub 2018 Sep 17.
4
Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.遗传性肾细胞癌综合征：诊断、监测和管理。
World J Urol. 2018 Dec;36(12):1891-1898. doi: 10.1007/s00345-018-2288-5. Epub 2018 Apr 21.
5
Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.胚系 BAP1 阳性患者：癌症监测的困境和拟议的跨学科共识监测策略。
Eur J Cancer. 2018 Mar;92:48-53. doi: 10.1016/j.ejca.2017.12.022. Epub 2018 Feb 3.
6
Radiological Surveillance Screening in Asymptomatic Succinate Dehydrogenase Mutation Carriers.无症状琥珀酸脱氢酶突变携带者的放射学监测筛查
J Endocr Soc. 2017 Jun 6;1(7):897-907. doi: 10.1210/js.2017-00230. eCollection 2017 Jul 1.
7
Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.希佩尔-林道综合征和遗传性嗜铬细胞瘤/副神经节瘤综合征：儿童期的临床特征、遗传学和监测建议。
Clin Cancer Res. 2017 Jun 15;23(12):e68-e75. doi: 10.1158/1078-0432.CCR-17-0547.
8
Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.非透明细胞肾细胞癌患者临床试验治疗的生存结局综合分析。
Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
9
Genetic predisposition to kidney cancer.肾癌的遗传易感性。
Semin Oncol. 2016 Oct;43(5):566-574. doi: 10.1053/j.seminoncol.2016.09.001. Epub 2016 Sep 22.
10
Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers.计算SDHB基因突变携带者头颈部副神经节瘤的最佳监测方案。
Fam Cancer. 2017 Jan;16(1):123-130. doi: 10.1007/s10689-016-9923-3.
Zotero 插件